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OBJECTIVES This study evaluated the efficacy of long-term treatment with the angiotensin-converting
enzyme (ACE) inhibitor trandolapril in diabetic patients with left ventricular dysfunction
after acute myocardial infarction (AMI).
BACKGROUND Patients with diabetes mellitus have a high mortality following AMI, probably due to a high
risk of congestive heart failure and reinfarction. Because ACE inhibition effectively reduces
progression of heart failure, it could be particularly beneficial in diabetic patients after AMI.
METHODS The study is a retrospective analysis using data from the Trandolapril Cardiac Evaluation
(TRACE) study, which was a randomized, double-blind, placebo-controlled trial of tran-
dolapril in 1,749 patients with AMI and ejection fraction #35%. The mean follow-up time
was 26 months.
RESULTS A history of diabetes was found in 237 (14%) of the 1,749 patients. Treatment with
trandolapril resulted in a relative risk (RR) of death from any cause for the diabetic group of
0.64 (95% confidence interval 0.45 to 0.91) versus 0.82 (0.69 to 0.97) for the nondiabetic
group. In the diabetic group, trandolapril reduced the risk of progression to severe heart
failure markedly (RR, 0.38 [0.21 to 0.67]), and no significant reduction of this end point was
found in the nondiabetic group.
CONCLUSIONS The ACE inhibition after myocardial infarction complicated by left ventricular dysfunction
appears to be of considerable importance in patients with diabetes mellitus by saving lives and
substantially reducing the risk of progression to severe heart failure. (J Am Coll Cardiol 1999;
34:83–9) © 1999 by the American College of Cardiology
Patients with diabetes mellitus have a poor prognosis after
acute myocardial infarction (AMI). In most patients stud-
ied, the mortality rate after AMI is reported to be approx-
imately twice that of patients without diabetes (1–3). The
excess mortality seems to be due to a higher risk of
congestive heart failure and reinfarction (4,5).
Angiotensin-converting enzyme (ACE) inhibition atten-
uates progression of heart failure and reduces mortality after
AMI (6–8). One important mechanism behind these effects
appears to be a beneficial influence on postinfarction left
ventricular remodeling (9). Other mechanisms have, how-
ever, been suggested and some of these could be of partic-
ular importance in diabetic patients. Hence, ACE inhibitors
can improve fibrinolytic balance, endothelial function, sym-
pathovagal balance and glycemic control in addition to their
ability to prevent or delay deterioration of renal function in
diabetic patients.
Recent studies have suggested that ACE inhibition in
diabetics with AMI is associated with a larger reduction in
short-term mortality and congestive heart failure compared
with nondiabetic patients (10,11). Analysis of long-term
benefit of ACE inhibition after AMI in a diabetic subgroup
is available only from the Survival and Ventricular Enlarge-
ment (SAVE) trial. In that study there was a trend for a
mortality benefit for patients without diabetes, although the
power was not adequate to make conclusions (12).
We hypothesize that long-term ACE inhibition could be
particularly beneficial in diabetic patients after AMI. No
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detailed analysis of long-term benefit of ACE inhibition
after AMI in high-risk diabetic patients is currently avail-
able. The purpose of this study was to evaluate the effect of
long-term treatment with trandolapril on mortality and
morbidity in diabetic patients with left ventricular dysfunc-
tion after AMI using data from the Trandolapril Cardiac
Evaluation (TRACE) study.
METHODS
Patients. The current study includes 1,749 patients from
the TRACE study, which was a randomized, double-blind,
placebo-controlled trial to determine whether patients with
left ventricular dysfunction shortly after myocardial infarc-
tion benefit from long-term oral ACE inhibition. Details of
the TRACE study design and results have been published
previously (6).
A total of 7,001 AMIs occurring in 6,676 patients were
screened consecutively for the TRACE study in 27 Danish
coronary care units between 1990 and 1992. Patients were
eligible for entry into the TRACE study if left ventricular
dysfunction was present two to six days after an enzyme-
verified AMI. Left ventricular systolic function was assessed
by echocardiography performed locally and subsequently
analyzed centrally by two members of the study group (13).
The criterion for left ventricular dysfunction was wall
motion index (WMI) #1.2 corresponding to an ejection
fraction (EF) #35%. A total of 2,606 patients were eligible
according to left ventricular systolic function, and 1,749
patients were included in the study. The most frequent
reasons for exclusion were mandatory need for ACE inhi-
bition (150 patients), cardiogenic shock (101), death during
screening (70), renal failure (65) and lack of informed
consent (218). Thirty-nine patients were excluded because
they did not tolerate a test dose of 0.5 mg trandolapril.
Study medication was started between days 3 and 7 after
the AMI. Initially the patients were given either 1 mg
trandolapril once daily or matching placebo. Target dose
was 4 mg administered once a day. If this dose was not
tolerated, patients could continue at a dose of 2 mg or 1 mg
daily; however, patients who did not tolerate 1 mg once
daily were withdrawn from the study.
The mean follow-up time was 26 months, ranging from
24 to 50 months. Excluding patients who died, 37.4% in the
trandolapril group and 35.5% in the placebo group were
withdrawn from study medication. Details of discontinua-
tion of the study drug have been described elsewhere (14).
The primary end point was death from any cause.
Information on survival status was available for all patients
at the end of the study in 1994 and also by October 1996,
six years after randomization of the first patient.
Predefined secondary end points were cardiovascular
death, sudden death, progression to severe/resistant heart
failure, recurrent infarction (fatal or nonfatal) and change in
WMI. Sudden death was defined as death within 1 h of
development of new symptoms, and progression in heart
failure was defined as hospital admission for heart failure,
death resulting from progressive heart failure, or heart
failure necessitating open-label ACE inhibition.
Information on diabetic status was obtained at screening
by case history, and diabetes was classified as being treated
with insulin, oral hypoglycemic agents or diet alone. If a
patient received both insulin and oral hypoglycemic agents
he was classified as treated with insulin.
Using data from the TRACE study the present study is a
retrospective analysis of the influence of having diabetes
mellitus on the efficacy of trandolapril in decreasing mor-
tality and morbidity after myocardial infarction complicated
by left ventricular dysfunction. Of the secondary end points,
change in WMI is omitted in this analysis as no difference
in this parameter between the treatment group and the
placebo group was found in the main study.
Statistics. Baseline characteristics for patients with and
without diabetes and for diabetic patients treated with
trandolapril or placebo were compared using the continuity-
adjusted chi-square test for discrete variables and the Wil-
coxon two-sample test for continuous variables. Mortality data
were analyzed on an intention-to-treat basis. Time-to-event
curves were generated with the use of Kaplan-Meier esti-
mates. Comparisons of mortality and secondary end points
were made using the Cox proportional hazards models. The
interaction of diabetes with the effect of ACE inhibition
was analyzed using a likelihood ratio test. A p value , 0.05
was considered significant. All calculations were generated
by the SAS software (SAS Institute, Cary, North Carolina).
Ethics. The TRACE study was approved by all Danish
regional ethics committees. All patients gave their informed
consent before inclusion in the randomized trial.
RESULTS
Clinical characteristics. A history of diabetes was found in
237 (14%) of the 1,749 randomized patients. Of these, 50
(21%) patients were treated with insulin, 118 (50%) with
oral hypoglycemic agents and 69 (29%) with diet alone.
Median duration of diabetes (5 to 95 percentiles) was 7 (1 to
26) years.
Baseline characteristics for patients with and without
Abbreviations and Acronyms
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diabetes are presented in Table 1. As expected, the two
groups differed in many ways. Diabetic patients were
slightly older, more often females, had a higher body mass
index (BMI) and were less often smokers. The diabetic
patients had a higher frequency of previous myocardial
infarction (MI), angina pectoris and arterial hypertension.
At randomization, patients with diabetes had higher systolic
blood pressure, slightly lower WMI and higher prevalence
of heart failure. A smaller proportion of the diabetic patients
received thrombolytic therapy. More diabetics were treated
with diuretics, whereas similar proportions of diabetics and
nondiabetics were treated with aspirin, beta-blockers, cal-
cium antagonists and nitrates at randomization. Treatment
with trandolapril was evenly distributed in the two groups.
In the diabetic group of 237 patients, 114 (48.1%) received
trandolapril, corresponding to 762 (50.4%) of the 1,512
nondiabetic patients (p 5 0.56). The target dose of 4 mg
trandolapril was tolerated by 85% in both groups, excluding
54 patients in the diabetic group and 288 in the nondiabetic
group, which did not survive the drug titration period.
Baseline characteristics were similar in the trandolapril-
treated and placebo-treated diabetic patients (Table 2). This
was also true for patients without diabetes but with two
exceptions: Compared with patients randomized to placebo,
patients randomized to trandolapril had a slightly higher
diastolic blood pressure (p 5 0.02) and a slightly higher
frequency of history of hypertension (p 5 0.04) (data not
shown).
Mortality. During follow-up, 126 patients (53%) in the
diabetic group died versus 547 (36%) in the nondiabetic
group. Fifty-one (45%) of the diabetic patients randomized
to trandolapril died versus 75 (61%) of the diabetics ran-
domized to placebo, resulting in a relative risk (RR) of death
from any cause in diabetic patients treated with trandolapril
of 0.64 (95% confidence interval [CI] 0.45 to 0.91). In the
nondiabetic group, 253 (33%) patients treated with tran-
dolapril died versus 294 (39%) of patients treated with
placebo, the relative risk (RR) of death being 0.82 (95% CI
0.69 to 0.97) (Fig. 1). The number needed to treat for
saving one life in 26 months was 6 in the diabetic group and
17 in the nondiabetic group. The interaction between
benefit on mortality from treatment with trandolapril and a
history of diabetes was not significant (p 5 0.3).
Similar results were obtained using a multivariate com-
parison including age, gender, BMI, smoking, previous MI,
hypertension, atrial fibrillation, ventricular fibrillation, con-
gestive heart failure, residual angina and WMI as covariates:
In the patients with diabetes, trandolapril was associated
with a risk reduction of 0.72 (95% CI 0.53 to 0.98), whereas
Table 1. Baseline Characteristics of 1,749 Patients With and Without a History of Diabetes
Diabetics
(n 5 237)
Nondiabetics
(n 5 1,512) p-Value
Mean age (6SD), years 70 (69) 68 (610) 0.003
Male gender, % 60 73 0.001
Mean BMI (6SD), kg/m2 26.2 (64.0) 25.6 (63.8) 0.03
Current or ex-smoker, % 35 50 0.001
Clinical history
Previous AMI, % 46 34 0.001
Angina pectoris, % 60 43 0.001
Treated hypertension, % 34 21 0.001
Cerebrovascular disease, % 12 8 0.06
Mean SBP (6SD), mm Hg 126 (619) 121 (617) ,0.001
Mean DBP (6SD), mm Hg 77 (611) 76 (610) 0.26
Mean s-creatinine (6SD),
mmol/liter
120 (633) 117 (635) 0.05
Mean peak CK-B (6SD),
U/liter
66 (669) 101 (6111) ,0.001
Mean WMI (6SD) 0.97 (60.19) 1.02 (60.18) ,0.001
Thrombolysis, % 30 48 0.001
Atrial fibrillation, % 28 25 0.48
Ventricular fibrillation, % 5 9 0.06
Killip class $2 at randomization, % 67 57 0.01
Medication at randomization
Aspirin, % 88 91 0.08
Beta-blockers, % 13 16 0.17
Calcium-antagonists, % 32 27 0.13
Diuretics, % 80 63 0.001
Nitrates, % 57 52 0.14
AMI 5 acute myocardial infarction; BMI 5 body mass index; CK-B 5 creatine kinase B; DBP 5 diastolic blood pressure;
SBP 5 systolic blood pressure; SD 5 standard deviation; WMI 5 wall motion index.
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in patients without diabetes the risk reduction was 0.89
(95% CI 0.78 to 1.02).
Two years after the end of the study period, four to six
years after randomization, the survival gain in diabetic
patients was maintained, RR of death in diabetic patients
treated with trandolapril being 0.68 (95% CI 0.50 to 0.91).
The corresponding RR for the nondiabetic patients was
0.88 (95% CI 0.77 to 1.02).
Subgrouping the diabetics according to their antidiabetic
treatment regimen indicated that the group treated with oral
hypoglycemic agents had the greatest survival benefit of
ACE inhibition. In fact, there was a significant interaction
between treatment with trandolapril and diabetes treated
with tablets with respect to mortality (p 5 0.04). However,
the numbers of insulin-treated and diet-treated diabetics
were limited and therefore the power of this analysis was not
adequate to draw definite conclusions.
Other clinical end points. Table 3 offers analyses of the
influence of treatment with trandolapril on the occurrence
of secondary end points in patients with and without
diabetes. Treatment with trandolapril reduced all secondary
endpoints by approximately 50% for the diabetic group,
though not significantly with regard to reinfarction (p 5
0.08). For the nondiabetic group only cardiovascular death
was reduced significantly (RR, 0.79 [0.66 to 0.96], p 5
0.02).
In the diabetic group, trandolapril reduced progression to
severe heart failure in particular (RR, 0.38 [0.21 to 0.67],
p , 0.001). The interaction between benefit from treatment
with trandolapril and diabetes was significant with regard to
this end point (p 5 0.03). Figure 2 shows that the rate of
progression in heart failure was much higher in the diabetic
group than in the nondiabetic group, which means that the
reduction in absolute risk of progression in heart failure was
substantial (21%) in the diabetic group compared with the
nondiabetic group (4%).
Adverse events. Serum(s)-creatinine decreased slightly
(1.3 mmol/liter) from baseline to one month after random-
ization in the diabetic group with no statistical difference
between the decrease in s-creatinine seen in the placebo-
treated and the trandolapril-treated patients. For nondia-
betic patients treated with trandolapril, s-creatinine in-
Figure 1. Cumulative mortality from all causes for patients with
(A) and without (B) diabetes receiving trandolapril or placebo.
Table 2. Baseline Characteristics of Diabetic Patients
Randomized to Placebo or Trandolapril
Placebo
(n 5 123)
Trandolapril
(n 5 114) p-Value
Mean age (6SD), years 70 (610) 69 (69) 0.37
Male gender, % 54 67 0.07
Previous AMI, % 43 49 0.42
History of AP, % 62 58 0.63
Treated hypertension, % 33 35 0.78
Mean SBP (6SD),
mm Hg
125 (619) 127 (620) 0.86
Mean DBP (6SD),
mm Hg
76 (611) 77 (611) 0.39
Mean WMI (6SD) 0.97 (60.20) 0.98 (60.19) 0.74
Thrombolysis 25 35 0.13
Killip class $2 at
randomization, %
66 68 0.89
AMI 5 acute myocardial infarction; AP 5 angina pectoris; DBP 5 diastolic blood
pressure; SBP 5 systolic blood pressure; SD 5 standard deviation; WMI 5 wall
motion index.
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creased marginally (0.7 mmol/liter), while it decreased (2.3
mmol/liter) for nondiabetic patients treated with placebo
(p 5 0.02).
During follow-up, the incidence of uremia was 1.9% in
the nondiabetic group and 3.4% in the diabetic group. In
both groups approximately 60% of the cases were seen in
patients receiving trandolapril.
Reasons for discontinuation of study medication were the
same in the diabetic group and the nondiabetic group.
DISCUSSION
This post hoc subgroup analysis of the TRACE data
indicates that patients with diabetes mellitus who have
suffered an AMI complicated by left ventricular dysfunction
have a substantial benefit from long-term ACE inhibition.
Mortality and, in particular, the secondary end point pro-
gression to severe heart failure were reduced markedly.
Indeed, the data revealed an interaction between diabetes
and the benefit from treatment with regard to progression to
severe heart failure.
The data material used in this analysis is unique because
two-thirds of consecutive patients with AMI and with left
ventricular dysfunction were included in the TRACE study.
Thus, the results are expected to be representative of infarct
patients with left ventricular dysfunction.
The diabetic population was 14%, which is close to the
12% (240 patients) in the Acute Ramipril Efficacy (AIRE)
study (8) but somewhat less than the 22% (492 patients) in
the SAVE study (7). The TRACE study and the AIRE
study were performed mostly in Europe, whereas the SAVE
study was performed in the U.S., where the frequency of
diabetes is higher (15,16). Baseline characteristics for the
diabetic patients resemble those of other infarct studies
(1,3,10). In both the diabetic group and the nondiabetic
group, baseline characteristics were well balanced between
placebo-treated and trandolapril-treated patients.
Mortality. The TRACE study, like other investigations in
the thrombolytic era, demonstrates that diabetic patients
comprise a high-risk population. The long-term mortality
(26 months) was 53% for the diabetic group, which is 47%
higher than for the nondiabetic group. Thus, it is important
to optimize the treatment strategies in this high-risk pop-
ulation.
In a retrospective univariate analysis of the large diabetic
population in the GISSI-3 (Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto Miocardico) study (2,790
patients) it was found that early treatment with lisinopril
after AMI was associated with a 30% reduction in six-week
mortality (10). The present TRACE data demonstrate a
36% reduction in 26-month mortality for diabetic patients
treated with trandolapril, a reduction that was maintained
two years after completion of the study. Possibly, the benefit
with regard to mortality is greater for the diabetic patients
than for the nondiabetic patients, but because of a relatively
small number of diabetic patients, the power to detect a
statistical significant interaction was not adequate.
Due to the high mortality of the diabetic patients, the
absolute reduction in mortality in this group becomes
substantial. For the diabetic group, the absolute mortality
reduction over two years was 16%, equivalent to a number
needed to treat of six patients for saving one life. The
corresponding figures for the nondiabetic group were 6%
and 17 patients.
Secondary end points. In addition to reduction in mortal-
ity, treatment with trandolapril resulted in an impressive
reduction in morbidity after AMI in the diabetic group.
There was a trend toward a substantial reduction in rein-
farction for the diabetic patients. Progression to severe heart
failure was reduced significantly, by more than 60%. The
reduction in progression to severe heart failure was signifi-
cantly higher for the patients with diabetes than for the
patients without diabetes. Because the rate of progression to
severe heart failure was also higher for diabetic patients, the
absolute reduction in this secondary end point becomes even
greater compared with nondiabetic patients.
Mechanisms for the effect of ACE inhibitors. The mech-
anism behind the effect of treatment with trandolapril in
diabetic patients with left ventricular dysfunction after AMI
is not simple nor fully understood. Because of structural,
functional and metabolic myocardial factors related to dia-
betes, the diabetic patient with AMI has a higher risk of left
ventricular remodeling, which is associated with a poor
prognosis (17,18). When adjusted for size of infarction,
patients with diabetes develop more congestive heart failure
than do patients without diabetes (19). Diabetic patients
with AMI generally have more extensive coronary artery
Table 3. Influence of Treatment With Trandolapril on the Occurrence of Secondary End Points
in Patients With and Without Diabetes
End Point
Diabetics Nondiabetics Interaction
RR (95% CI) p RR (95% CI) p p
Cardiovascular death 0.56 (0.37–0.85) 0.01 0.79 (0.66–0.96) 0.02 0.17
Sudden death 0.46 (0.25–0.85) 0.01 0.84 (0.63–1.12) 0.23 0.09
Reinfarction 0.55 (0.29–1.07) 0.08 0.93 (0.69–1.26) 0.65 0.15
Progression in HF 0.38 (0.21–0.67) ,0.001 0.81 (0.63–1.04) 0.10 0.03
CI 5 confidence interval; HF 5 heart failure; RR 5 relative risk.
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disease and a higher frequency of previous silent infarction
(3,20,21). A likely coexistence of diabetic cardiomyopathy
or hypertension can possibly worsen myocardial damage. It
has previously been suggested that hypertensives with AMI
and left ventricular dysfunction may derive particular benefit
from ACE inhibition (22), and in the present study the
diabetic patients have a higher frequency of arterial hyper-
tension. During ischemia the diabetic patient experiences
decreased myocardial glucose uptake leading to suppressed
adenosine triphosphate (ATP) production and myocardial
contractile dysfunction (23). Because diabetic patients may
be particularly prone to ventricular remodeling, ACE inhib-
itors may prevent death and progression in heart failure by
attenuating this deleterious alteration in cardiac geometry.
In addition, ACE inhibitors counteract many of the
established and putative mechanisms resulting in increased
mortality of diabetic patients with AMI. Fibrinolytic bal-
ance can be improved by ACE inhibition in patients with
AMI (24). Endothelial dysfunction can be attenuated by
ACE inhibition in patients with coronary artery disease
(25). For type 2 diabetics, ACE inhibitors have been shown
to improve insulin sensitivity and glycemic control (26).
Finally, it has been demonstrated that baroreflex sensitivity
and heart rate variability reflecting cardiac autonomic con-
trol can be favorably modified by ACE inhibitors in patients
with AMI (27,28). Autonomic imbalance, which is a
complication of diabetes mellitus, is associated with an
increased risk for sudden death (29), a mode of death that
tends to be reduced mostly for the diabetic patients in the
present study.
The beneficial effect of trandolapril in the diabetic group
was not counteracted by a higher frequency of renal adverse
events. Diabetic patients did not experience a higher inci-
dence of uremia as a result of treatment with trandolapril
compared with nondiabetic patients. Initial change in
s-creatinine from baseline to one month after randomiza-
tion was similar for patients with and without diabetes.
Study limitations. No prospective analysis of the benefit of
ACE inhibition in diabetics with AMI exists, and such a
study is not likely to be conducted. The main limitation of
this study was the fact that it was retrospective and based on
subgroup analysis. The results must therefore be interpreted
with caution (30). The magnitude of the benefit from
treatment with trandolapril in the diabetic subgroup, how-
ever, was striking and, indeed, clinically relevant. Further-
more, as discussed previously, the results can be explained by
plausible underlying mechanisms.
Because this study was not predefined, the diagnosis of
diabetes was based on history obtained at screening, and no
laboratory values on glycemic status were available. The
diabetic patients were not classified according to the type of
diabetes, but at least 80% must have had type 2 diabetes
according to their treatment mode. Owing to the relatively
low number of diabetics and the lack of classification
according to type, the diabetics were pooled in one group.
Among the nondiabetic patients a proportion with unrec-
ognized diabetes must be present. In a previous study, an
overall prevalence of undiagnosed diabetes mellitus of 5.3%
in patients with MI was estimated (31). If such patients in
our study had been classified correctly, they might have
tended to increase the difference in benefit observed be-
tween diabetics and nondiabetics. Conversely, some of the
diabetic patients treated with diet only may not have
fulfilled the diagnosis of diabetes.
Conclusions. Bearing the limitations of the study in mind,
we conclude that long-term treatment with trandolapril
after myocardial infarction complicated by left ventricular
dysfunction appears to be of considerable importance in
Figure 2. Rate of progression to severe or resistant heart failure for
patients with (A) and without (B) diabetes receiving trandolapril or
placebo.
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patients with diabetes mellitus by saving lives and substan-
tially reducing the risk of progression to severe heart failure.
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